An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19

  • STATUS
    Recruiting
  • participants needed
    100
  • sponsor
    Canadian Medical and Surgical Knowledge Translation Research Group
Updated on 19 February 2024
fever
dyspnea
cough
pharyngitis
covid-19
myalgia
SARS
sore throat
icosapent ethyl
throat
acute respiratory syndrome (sars)

Summary

This is a 14-day long prospective, multi-site, two-armed, randomized, open-label study that will enroll approximately 100 adult outpatients in Canada who have received a positive SARS-CoV-2 test result within the preceding 72 hours. Participants will be randomized (1:1) to receive either icosapent ethyl (4 g BID for 3 days, then 2 g BID for the subsequent 11 days) or usual care. Blood samples will be collected to determine if icosapent ethyl use lowers circulating pro-inflammatory biomarkers.

Details
Condition Inflammatory Response, Covid 19
Age 18-75 years
Treatment Icosapent ethyl
Clinical Study IdentifierNCT04412018
SponsorCanadian Medical and Surgical Knowledge Translation Research Group
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Positive local SARS-CoV-2 test result within the preceding 72 hours
At least one of the following symptoms
Fever
Cough
Sore throat
Shortness of breath
Myalgia

Exclusion Criteria

Individuals currently participating in another interventional trial that will or may interfere with the primary outcome
Hospitalized individuals
Individuals who have a current medical condition for which life expectancy is less than 3 months
Individuals with a history of acute end-organ injury (e.g. myocardial infarction, stroke, hospitalization for acute lung, liver or kidney disease) within the last month
Individuals with active severe liver disease
Individuals with a history of acute or chronic pancreatitis
Women who are pregnant, may be pregnant, are planning on becoming pregnant, or are lactating
Women of child-bearing potential who are not using at least one form of highly effective (hormonal contraceptives [e.g. combined oral contraceptives, patch, vaginal ring, injectables, and implants]; intrauterine device or intrauterine system; tubal ligation or whose partner has had a vasectomy) and one effective (barrier methods such male condom, female condom, cervical cap, diaphragm, or contraceptive sponge) method of contraception
Individuals with a history of hemodynamic instability within past 72 hours including a systolic blood pressure of <95 mmHg and/or a diastolic blood pressure of <50 mmHg
Individuals with known hypersensitivity to fish and/or shellfish, or ingredients of IPE
Individuals with any other condition which, in the opinion of the Investigator, would place the participant at increased risk, preclude obtaining voluntary consent or confound the objectives of study
Individuals who are unable to swallow IPE capsules whole
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.